Acute side effects after definitive stereotactic body radiation therapy (SBRT) for patients with clinically localized or locally advanced prostate cancer: a single institution prospective study

Jorgo, Kliton; Polgar, Csaba; Stelczer, Gabor; Major, Tibor; Gesztesi, Laszlo; Agoston, Peter

doi:10.2478/raon-2021-0031

Abstract

Background

The aim of the study was to evaluate acute side effects after extremely hypofractionated intensity-modulated radiotherapy (IMRT) with stereotactic body radiation therapy (SBRT) for definitive treatment of prostate cancer patients.

Patients and methods

Between February 2018 and August 2019, 205 low-, intermediate- and high-risk prostate cancer patients were treated with SBRT using “CyberKnife M6” linear accelerator. In low-risk patients 7.5–8 Gy was delivered to the prostate gland by each fraction. For intermediate- and high-risk disease a dose of 7.5–8 Gy was delivered to the prostate and 6–6.5 Gy to the seminal vesicles by each fraction with a simultaneous integrated boost (SIB) technique. A total of 5 fractions (total dose 37.5–40 Gy) were given on every second working day. Acute radiotherapy-related genitourinary (GU) and gastrointestinal (GI) side effects were assessed using Radiation Therapy Oncology Group (RTOG) scoring system.

Results

Of the 205 patients (28 low-, 115 intermediate-, 62 high-risk) treated with SBRT, 203 (99%) completed the radiotherapy as planned. The duration of radiation therapy was 1 week and 3 days. The frequencies of acute radiotherapy-related side effects were as follows: GU grade 0 – 17.1%, grade I – 30.7%, grade II – 50.7%, grade III – 1.5%; and GI grade 0 – 62.4%, grade I–31.7%, grade II–5.9%, grade III–0%. None of the patients developed grade ≥ 4 acute toxicity.

Conclusions

SBRT with a total dose of 37.5–40 Gy in 5 fractions appears to be a safe and well tolerated treatment option in patients with prostate cancer, associated with slight or moderate early side effects. Longer follow-up is needed to evaluate long-term toxicity and biochemical control.

References

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin 2018; 68: 394-24. doi: 10.3322/caac.21492
Open DOI Search in Google Scholar Back to article
Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer 2018; 103: 356-87. doi: 10.1016/j.ejca.2018.07.005
Open DOI Search in Google Scholar Back to article
Attard G, Parker C, Eeles R, Schröder F, Tomlins S, Tannock I, et al. Prostate cancer. Lancet 2016; 387: 70-82. doi: 10.1016/S0140-6736(14)61947-4
Open DOI Search in Google Scholar Back to article
Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends – an update. Cancer Epidemiol Biomarkers Prev 2016; 25: 16-27. doi: 10.1158/1055-9965
Open DOI Search in Google Scholar Back to article
Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol 2014; 65: 124-37. doi: 10.1016/j.eururo.2013.09.046
Open DOI Search in Google Scholar Back to article
Donovan JL, Hamdy FC, Lane JA, Mason M, Metcalfe C, Walsh E, et al. Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med 2016; 375: 1425-37. doi: 10.1056/NEJMoa1606221
Open DOI Search in Google Scholar Back to article
Hamdy FC, Donovan JL, Lane JA. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med 2016; 375: 1415-24. doi: 10.1056/NEJMoa1606220
Open DOI Search in Google Scholar Back to article
Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 1999; 43: 1095-101. doi: 10.1016/s0360-3016(98)00438-6
Open DOI Search in Google Scholar Back to article
Arcangeli S, Greco C. Hypofractionated radiotherapy for organ-confined prostate cancer: is less more? Nat Rev Urol 2016; 13: 400-8. doi: 10.1038/nrurol.2016.106
Open DOI Search in Google Scholar Back to article
Zaorsky NG, Studenski MT, Dicker AP, Gomella L, Den R. Stereotactic body radiation therapy for prostate cancer: is the technology ready to be the standard of care? Cancer Treat Rev 2013; 39: 212-8. doi: 10.1016/j.ctrv.2012.10.003
Open DOI Search in Google Scholar Back to article
Dearnaley D, Syndikus I, Mossop H, Bidmead M, Bloomfield D, Clark C, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol 2016; 17: 1047-60. doi: 10.1016/S1470-2045(16)30102-4
Open DOI Search in Google Scholar Back to article
Catton CN, Lukka H, Gu CS, Martin J, Supiot S, Chung P, et al. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. J Clin Oncol 2017; 35: 1884-90. doi: 10.1200/JCO.2016.71.7397
Open DOI Search in Google Scholar Back to article
Lee WR, Dignam JJ, Amin MB, Bruner D, Low D, Swanson G, et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. J Clin Oncol 2016; 34: 2325-32. doi: 10.1200/JCO.2016.67.0448
Open DOI Search in Google Scholar Back to article
Aluwini S, van Rooij P, Hoogeman M, Kirkels W, Kolkman-Deurloo I, Bangma C. Stereotactic body radiotherapy with a focal boost to the MRI-visible tumor as monotherapy for low- and intermediate-risk prostate cancer: early results. Radiat Oncol Lond Engl 2013; 8: 84. doi: 10.1186/1748-717X-8-84
Open DOI Search in Google Scholar Back to article
Loblaw A, Cheung P, D’Alimonte L, Deabreu A, Mamedov A, Zhang L, et al. Prostate stereotactic ablative body radiotherapy using a standard linear accelerator: toxicity, biochemical, and pathological outcomes. Radiother Oncol J Eur Soc Ther Radiol Oncol 2013; 107: 153-8. doi: 10.1016/j.radonc.2013.03.022
Open DOI Search in Google Scholar Back to article
King CR, Brooks JD, Gill H, Presti Jr J. Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int J Radiat Oncol Biol Phys 2012; 82: 877-82. doi: 10.1016/j.ijrobp.2010.11.054
Open DOI Search in Google Scholar Back to article
Jorgo K, Ágoston P, Szabó Z, Major T, Polgár Cs. [Use of gold radionuclide markers implanted into the prostate for image-guided radiotherapy in prostate cancer: side effects caused by the marker implantation]. [Hungarian]. Magy Onkol 2014; 58: 182-87.
Search in Google Scholar Back to article
Jorgo K, Agoston P, Major T, Takácsi-Nagy Z, Polgár Cs. Transperineal gold marker implantation for image-guided external beam radiotherapy of prostate cancer. A single institution, prospective study. Strahlenther Onkol 2017; 193: 452-58. doi: 10.1007/s00066-017-1104-2.
Open DOI Search in Google Scholar Back to article
D’Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen M. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol 2003; 21: 2163-72. doi: 10.1200/JCO.2003.01.075
Open DOI Search in Google Scholar Back to article
Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995; 30: 1341-46. doi: 10.1016/0360-3016(95)00060-C
Open DOI Search in Google Scholar Back to article
Holmboe ES, Concato J. Treatment decisions for localized prostate cancer: asking men what’s important. J Gen Intern Med 2000; 15: 694-701. doi: 10.1046/j.1525-1497.2000.90842.x
Open DOI Search in Google Scholar Back to article
Dandapani SV, Sanda MG. Measuring health-related quality of life consequences from primary treatment for early-stage prostate cancer. Semin Radiat Oncol 2008; 18: 67-72. doi: 10.1016/j.semradonc.2007.10.001
Open DOI Search in Google Scholar Back to article
Hodges JC, Lotan Y, Boike TP, Benton R, Barrier A, Timmerman R. Cost-effectiveness analysis of SBRT versus IMRT: an emerging initial radiation treatment option for organ-confined prostate cancer. Am J Manag Care 2012; 18: e186-93. doi: 10.1200/JOP.2012.000548
Open DOI Search in Google Scholar Back to article
Brand DH, Tree AC, Ostler P, van der Voet H, Loblaw A, Chu W, et al. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial. Lancet Oncol 2019; 20: 1531-43. doi: 10.1016/S1470-2045(19)30569-8
Open DOI Search in Google Scholar Back to article
Widmark A, Gunnlaugsson A, Beckman L, Thellenberg-Karlsson C, Hoyer M, Lagerlund M, et al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet 2019; 394: 385-95. doi: 10.1016/S0140-6736(19)31131-6
Open DOI Search in Google Scholar Back to article
Madsen BL, Hsi RA, Pham HT, Fowler J, Esagui L, Corman J. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5Gy in five fractions for localized disease: first clinical trial results. Int J Radiat Oncol Biol Phys 2007; 67: 1099-105. doi: 10.1016/j.ijrobp.2006.10.050
Open DOI Search in Google Scholar Back to article
Katz AJ, Santoro M, Ashley R, Diblasio F, Witten M, et al. Stereotactic body radiotherapy for organ-confined prostate cancer. BMC Urol 2010; 10: 1. doi: 10.1186/1471-2490-10-1
Open DOI Search in Google Scholar Back to article
Boike TP, Lotan Y, Cho LC, Brindle J, DeRose P, Xie X, et al. Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer. J Clin Oncol 2011; 29: 2020-26. doi: 10.1200/JCO.2010.31.4377
Open DOI Search in Google Scholar Back to article
Freeman DE, King CR. Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes. Radiat Oncol 2011; 6: 3. doi: 10.1186/1748-717X-6-3
Open DOI Search in Google Scholar Back to article
Jabbari S, Weinberg VK, Kaprealian T, Hsu I, Ma L, Chuang C, et al. Stereotactic body radiotherapy as monotherapy or post-external beam radiotherapy boost for prostate cancer: technique, early toxicity, and PSA response. Int J Radiat Oncol Biol Phys 2012; 82: 228-34. doi: 10.1016/j.ijrobp.2010.10.026
Open DOI Search in Google Scholar Back to article
McBride SM, Wong DS, Dombrowski JJ, Harkins B, Tapella P, Hanscom H, et al. Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: preliminary results of a multi-institutional phase 1 feasibility trial. Cancer 2012; 118: 3681-90. doi: 10.1002/cncr.26699
Open DOI Search in Google Scholar Back to article
Bolzicco G, Favretto MS, Satariano N, Scremin E, Tambone C, Tasca A. A single-center study of 100 consecutive patients with localized prostate cancer treated with stereotactic body radiotherapy. BMC Urol 2013; 13: 49. doi: 10.1186/1471-2490-13-49
Open DOI Search in Google Scholar Back to article
Oliai C, Lanciano R, Sprandio B, Yang J, Lamond J, Arrigo S, et al. Stereotactic body radiation therapy for the primary treatment of localized prostate cancer. J Radiat Oncol 2013; 2: 63-70. doi: 10.1007/s13566-012-0067-2
Open DOI Search in Google Scholar Back to article
Mantz C. A Phase II trial of stereotactic ablative body radiotherapy for low-risk prostate cancer using a non-robotic linear accelerator and realtime target tracking: Report of toxicity, quality of life, and disease control outcomes with 5-year minimum follow-up. Front Oncol 2014; 4: 279. doi: 10.3389/fonc.2014.00279
Open DOI Search in Google Scholar Back to article
Chen LN, Suy S, Wang H, Bhagat A, Woo J, Moures R, et al. Patient-reported urinary incontinence following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer. Radiat Oncol 2014; 9: 148. doi: 10.1186/1748-717X-9-148
Open DOI Search in Google Scholar Back to article
Anwar M, Weinberg V, Seymour Z, Hsu J, Roach M 3rd, Gottschalk A. Outcomes of hypofractionated stereotactic body radiotherapy boost for intermediate and high-risk prostate cancer. Radiat Oncol 2016; 11: 8. doi: 10.1186/s13014-016-0585-y
Open DOI Search in Google Scholar Back to article
Hannan R, Tumati V, Xie XJ, Cho LC, Kavanagh B, Brindle J, et al. Stereotactic body radiation therapy for low and intermediate risk prostate cancer-Results from a multi-institutional clinical trial. Eur J Cancer 2016; 59: 142-51. doi: 10.1016/j.ejca.2016.02.014
Open DOI Search in Google Scholar Back to article
Murthy V, Sinha S, Kannan S, Datta D, Das R, Bakshi G, et al. Safety of prostate stereotactic body radiation therapy after Transurethral Resection of Prostate (TURP): A propensity score matched pair analysis. Pract Radiat Oncol 2019; 5: 347-53. doi: 10.1016/j.prro.2019.04.003
Open DOI Search in Google Scholar Back to article
Wang K, Chen RC, Kane B, Medbery C, Underhill K, Gray J, et al. Patient and dosimetric predictors of genitourinary and bowel quality of life after prostate SBRT: Secondary analysis of a multi-institutional trial. Int J Radiat Oncol Biol Phys 2018; 102: 1430-37. doi: 10.1016/j.ijrobp.2018.07.191
Open DOI Search in Google Scholar Back to article
Bolzicco G, Favretto MS, Satariano N, Scremin E, Tambone C, Tasca A. A single-center study of 100 consecutive patients with localized prostate cancer treated with stereotactic body radiotherapy. BMC Urol 2013; 13: 49. doi: 10.1186/1471-2490-13-49
Open DOI Search in Google Scholar Back to article
Katz AJ, Kang J. Quality of life and toxicity after SBRT for organ-confined prostate cancer, a 7-year study. Front Oncol 2014; 4: 301. doi: 10.3389/ fonc.2014.00301
Open DOI Search in Google Scholar Back to article
Gurka MK, Chen LN, Bhagat A, Moures R, Kim SJ, Yung T, et al. Hematuria following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer. Radiat Oncol 2015; 10: 44. doi: 10.1186/s13014-015-0351-6
Open DOI Search in Google Scholar Back to article